publications. We wish to advise historical scientific literature documenting the use of arsenical compounds in veterinary (and human) medicine that adds to the suggestions on the origin of arsenic resistance previously proposed. In 1935, E. Roberts and W. M. Dawson of the University of Illinois [8] tested experimentally the detrimental effects of arsenical Fowler solution. (The English physician Thomas Fowler invented the solution containing 1% potassium arsenite in 1786; it was prescribed to cure periodic fever and syphilis, and later as a tonic. Also called Kali arsenicosum, Kali arseniatum, Liquor potassii arseniti, or Liquor potassae arsenitis, it was in use until the late 1950s. Of note, considering the role of rodents as immune reservoirs of Y. pestis, the actual wide use of potassium arsenite as a pesticide and rodenticide raises concern.) The preparation reported in their article, containing 1% arsenic trioxide, was popular as a farm-animal feeding to accelerate fat accumulation and to obtain lucent hair [8] . The medical use for which they were usually prescribed to humans included intermittents, or ague, the archaic terms for periodic or malarial fever. Interestingly, several years before, in 1796, Potter of the first American medical school at the University of Pennsylvania envisaged the deleterious effects of arsenic in his treatise [11] , and testifies of arsenic use in the early colonized United States. The Italian physician Bartolomeo Alizeri, in a publication of 1721 [12] , warns against the use of arsenical compounds to cure human plague. An interesting observation of Alizeri underlines the efficacy of arsenic in temporarily attenuating some clinical manifestations of the disease, remarking on the subsequent insurgence of more severe symptoms in arsenic-exposed patients [12] . We are tempted to speculate that Alizeri anticipates the existence of Y. pestis strains resistant to arsenic in Europe in the 18th century. These early scientific writings testify to the use of arsenic in Western countries for centuries and in the United States for almost 150 years. Actually, arsenical and antimonial compounds, as part of the Pharmacopoeia and Materia Medica (Medical Materials), including plants, minerals, and animal derivatives, were in use in Europe upon the influence of the Middle Ages physicians Avicenna (Ibn Sina, 980-1037) and Averroes (Ibn Rushd, 1126-1198) and of Paracelsus (Theophrastus Phillipus Aureolus Bombastus von Hohenheim [1493-1541], German-Swiss physician and scholar) teachings in Renaissance medical schools. In the "Book of the Plague" ( published posthumously in 1576), Paracelsus suggested amulets containing arsenic or quicksilver (xenexicon), based on his experience to prevent and cure the plague that was raging in Switzerland in 1534. Paracelsus's treatises on medicine were written in accessible vernacular German, in opposition to the official Latin Galenic texts. The medical approach of Paracelsus spread and persisted for centuries (the first edition of the Latin translation of Paracelsus's collected writings appeared in 1658 in England, under the auspices of the newborn Royal Society), was diffused in the United States after colonization, and was still in use until the middle 19th century. In Eastern countries, traditional Chinese medicine prescribes ointments for topical use or beverages containing arsenic sulfide (realgar) to treat human and animal diseases, including swine hyperpyrexia syndrome. The discontinuous exposure to low, nontoxic doses of arsenical preparations present in almost all coded pharmacopoeias in Western and Eastern countries might have favored the development and exchange of plasmids carrying arsenic resistance in host microorganisms. It cannot be excluded that farm animals arriving from England and Germany during the colonization of America could have already been exposed to low-dose arsenic and become carriers of arsenic-resistant bacteria in their gut.
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